The 78 rating InvestorsObserver gives to Elevation Oncology Inc (ELEV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 92 percent of stocks in the Biotechnology industry, ELEV’s 78 overall rating means the stock scores better than 78 percent of all stocks.
ELEV has an Overall Score of 78. Find out what this means to you and get the rest of the rankings on ELEV!
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 78 means the stock is more attractive than 78 percent of stocks.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Elevation Oncology Inc Stock Today?
Elevation Oncology Inc (ELEV) stock has gained 1.2% while the S&P 500 is lower by -0.19% as of 11:56 AM on Monday, Mar 11. ELEV has gained $0.05 from the previous closing price of $4.57 on volume of 165,136 shares. Over the past year the S&P 500 is up 32.64% while ELEV has gained 317.12%. ELEV lost -$2.16 per share the over the last 12 months.
Click Here to get the full Stock Report for Elevation Oncology Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
